Latest news and press releases about Alzamend Neuro Inc (ALZN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a meth...
Price
| Price | $1.83 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.33 |
| EV / EBITDA | -0.64 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -277.71% |
| Return on Invested Capital | -1195.68% |
| Return on Assets | -421.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · ADIL · APRE · BCDA · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ALZN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks